AEON Biopharma (AEON)
XASE:AEON
Top Page
AEON Biopharma
(NYSE MKT:AEON)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.90
▼(-18.18% Downside)
Action:ReiteratedDate:04/08/26
The score is held down primarily by weak financial performance (zero revenue, recurring losses/cash burn, and negative equity with rising debt). Technical indicators also reflect weak momentum and a price below key moving averages. Corporate events are mixed but include heightened listing-compliance risk, and valuation offers limited support due to loss-making results and no dividend.
Positive Factors
Regulatory clarity on biosimilar pathway
Constructive FDA Type 2a feedback gives a clear analytical framework for ABP-450, reducing scientific and regulatory ambiguity. This durable guidance focuses development work for 2026, lowers program execution risk, and improves the odds of advancing to Type 2b discussions and eventual approval across indications.
Negative Factors
Stressed balance sheet
Persistent negative equity, minimal assets and materially higher debt constrain financial flexibility and raise dilution and refinancing risk. This structural weakness increases vulnerability to funding disruptions and underpins the company’s NYSE American noncompliance exposure over the 2–6 month horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory clarity on biosimilar pathway
Constructive FDA Type 2a feedback gives a clear analytical framework for ABP-450, reducing scientific and regulatory ambiguity. This durable guidance focuses development work for 2026, lowers program execution risk, and improves the odds of advancing to Type 2b discussions and eventual approval across indications.
Read all positive factors
AEON Biopharma (AEON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.77M
Dividend YieldN/A
Average Volume (3M)273.24K
Price to Earnings (P/E)―
Beta (1Y)1.12
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.24
Shares Outstanding25,303,059
10 Day Avg. Volume605,674
30 Day Avg. Volume273,237
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.17K
Enterprise Value/Ebitda-2.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-50.4
Revenue Forecast (FY)$16.30M
AEON Biopharma Business Overview & Revenue Model
Company Description
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gas...
How the Company Makes Money
null...
AEON Biopharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
15
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -78.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -16.82M | -27.73M | -52.74M | -48.36M | -36.88M |
| Net Income | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M |
Balance Sheet | |||||
| Total Assets | 5.56M | 3.14M | 6.84M | 10.78M | 6.44M |
| Cash, Cash Equivalents and Short-Term Investments | 3.01M | 13.00K | 5.16M | 9.75M | 5.13M |
| Total Debt | 35.74M | 12.96M | 278.00K | 131.53M | 86.89M |
| Total Liabilities | 60.59M | 31.71M | 159.89M | 281.19M | 230.26M |
| Stockholders Equity | -55.03M | -28.57M | -153.04M | -287.50M | -234.94M |
Cash Flow | |||||
| Free Cash Flow | -17.31M | -20.29M | -47.83M | -35.89M | -28.60M |
| Operating Cash Flow | -17.31M | -20.29M | -47.83M | -35.58M | -28.43M |
| Investing Cash Flow | -4.00K | 0.00 | 0.00 | -306.00K | -170.00K |
| Financing Cash Flow | 20.30M | 15.15M | 14.00M | 40.51M | 13.56M |
AEON Biopharma Technical Analysis
Negative
1.10
Price Trends
1.09
Negative
1.03
Negative
0.93
Negative
Market Momentum
-0.05
Positive
39.06
Neutral
11.52
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEON, the sentiment is Negative. The current price of 1.1 is above the 20-day moving average (MA) of 1.05, above the 50-day MA of 1.09, and above the 200-day MA of 0.93, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 39.06 is Neutral, neither overbought nor oversold. The STOCH value of 11.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AEON.
AEON Biopharma Risk Analysis
AEON Biopharma disclosed 66 risk factors in its most recent earnings report. AEON Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AEON Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $7.67M | -0.46 | -684.86% | ― | ― | 96.75% | |
48 Neutral | $12.28M | -0.56 | -406.72% | ― | ― | 57.97% | |
46 Neutral | $6.97M | -5.72 | -9.02% | ― | ― | -1979.68% | |
42 Neutral | $22.77M | -0.09 | 0.02% | ― | ― | ― | |
| ― | $6.13M | -5.23 | ― | ― | ― | 65.45% |
* Healthcare Sector Average
AEON
AEON Biopharma
0.90
0.47
109.30%
IMNN
Imunon
3.13
-8.22
-72.42%
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.34
-2.34
-50.00%
APM
Aptorum Group
0.86
0.11
15.54%
RNAZ
TransCode Therapeutics
8.36
-2.32
-21.72%
AEON Biopharma Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
AEON Biopharma Receives Additional NYSE American Noncompliance Notice
Negative
Apr 3, 2026
On March 31, 2026, AEON Biopharma received an additional notice from NYSE American that it is not in compliance with Section 1003(a)(ii), which requires at least $4 million in stockholders’ equity when a company has losses in three of its fo...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
AEON Biopharma Strengthens Finance Leadership with New CFO
Positive
Mar 9, 2026
On March 6, 2026, AEON Biopharma’s board appointed veteran biotech executive John Bencich as chief financial officer effective March 9, 2026, and principal financial officer effective April 1, 2026, aligning its finance leadership with its p...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and ComplianceShareholder Meetings
AEON Biopharma Advances Biosimilar Program and Debt Reduction
Positive
Jan 21, 2026
On January 21, 2026, AEON Biopharma reported that it had held its scheduled Biosimilar Product Development Type 2a meeting with the U.S. Food and Drug Administration regarding ABP-450, an important procedural step expected to guide the next phase ...
Business Operations and StrategyRegulatory Filings and Compliance
AEON Biopharma Releases Updated Investor Presentation Under Reg FD
Neutral
Jan 12, 2026
On January 12, 2026, AEON Biopharma, Inc. made a new corporate presentation available in the investor relations section of its website and indicated that management may use this material in future meetings about the company. The company emphasized...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.